SCHEMBL1124875

SCHEMBL1124875

O=Cc1ccc(-c2cccc(CC(=O)O)c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.55
GRIN3B O60391 1/20 0.55
GRIN1 Q05586 1/20 0.55
GRIN2A Q12879 1/20 0.55
GRIN2B Q13224 1/20 0.55
GRIN2C Q14957 1/20 0.55
GRIN3A Q8TCU5 1/20 0.55
ABCC4 O15439 1/20 0.53
LMNA P02545 1/20 0.53
GAA P10253 1/20 0.53
TSHR P16473 1/20 0.53
PTGS1 P23219 1/20 0.53
HTT P42858 1/20 0.53
TRIM24 O15164 1/20 0.51
TRIM33 Q9UPN9 1/20 0.51
PTGS2 P35354 1/20 0.51
DRD1 P21728 1/20 0.48
ENPP2 Q13822 2/20 0.47
PLA2G10 O15496 1/20 0.47
PLA2G2A P14555 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28032595 0.86 LMNA (0.63) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL12607534 0.86 DRD1 (0.47) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL9251496 0.84 ABCC4 (0.74) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL538397 0.84 ABCC4 (0.67) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL1125736 0.83 ABCC4 (0.64) ABCC4LMNAGAATSHRPTGS1
SCHEMBL1124854 0.82 ALDH1A1 (0.47) GAATRIM24TRIM33DRD1BCL2
SCHEMBL18229517 0.81 PRKCI (0.56) TRIM24TRIM33DRD1BCL2ACMSD
SCHEMBL3417462 0.81 GRIN2D (0.59) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL2388359 0.81 AKR1B1 (0.54) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Methyl Alcohol SCHEMBL7855784 0.81 ABCC4 (0.62) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-2284157-A1 Quinolines useful in treating cardiovascular disease Wyeth (US) 2011-02-16 EP disclosed
US-7576215-B2 Quinolines and pharmaceutical compositions thereof WYETH (US) 2009-08-18 US disclosed
EP-1692111-A2 QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE Wyeth, A Corporation of the State of Delaware (US) 2006-08-23 EP disclosed
WO-2005058834-A2 QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE WYETH (US) 2005-06-30 WO disclosed
US-20050131014-A1 Quinolines useful in treating cardiovascular disease WYETH (US) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131014-A1 Quinolines useful in treating cardiovascular disease NR1H2, NR1H3, SREBF1 GRIN2D 4241/4885GRIN3B 2402/4885GRIN1 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.